4.7 Article

Dickkopf-related protein 1 (Dkk1) regulates the accumulation and function of myeloid derived suppressor cells in cancer

Journal

JOURNAL OF EXPERIMENTAL MEDICINE
Volume 213, Issue 5, Pages 827-840

Publisher

ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20150950

Keywords

-

Funding

  1. National Institutes of Health (NIH) [P30 AR057235, P50 CA94056ADD]
  2. NIH [R01 AR053628, AR066551, 5 R01CA151518]
  3. Shriners Hospital grant [85100]
  4. American Society for Bone and Mineral Research Gap grant
  5. Siteman Cancer Center grant
  6. North American Spine Society
  7. Alvin J. Siteman Cancer Research Fund at Washington University in St. Louis, MO
  8. American Cancer Society Research Scholar Award [KL2 TR000450, 2R01 CA097250]
  9. Pancreatic Cancer Action Network
  10. Lustgarten foundation

Ask authors/readers for more resources

Tumor-stroma interactions contribute to tumorigenesis. Tumor cells can educate the stroma at primary and distant sites to facilitate the recruitment of heterogeneous populations of immature myeloid cells, known as myeloid-derived suppressor cells ( MDSCs). MDSCs suppress T cell responses and promote tumor proliferation. One outstanding question is how the local and distant stroma modulate MDSCs during tumor progression. Down-regulation of beta-catenin is critical for MDSC accumulation and immune suppressive functions in mice and humans. Here, we demonstrate that stroma-derived Dickkopf-1 ( Dkk1) targets beta-catenin in MDSCs, thus exerting immune suppressive effects during tumor progression. Mice bearing extraskeletal tumors show significantly elevated levels of Dkk1 in bone microenvironment relative to tumor site. Strikingly, Dkk1 neutralization decreases tumor growth and MDSC numbers by rescuing beta-catenin in these cells and restores T cell recruitment at the tumor site. Recombinant Dkk1 suppresses beta-catenin target genes in MDSCs from mice and humans and anti-Dkk1 loses its antitumor effects in mice lacking beta-catenin in myeloid cells or after depletion of MDSCs, demonstrating that Dkk1 directly targets MDSCs. Furthermore, we find a correlation between CD15(+) myeloid cells and Dkk1 in pancreatic cancer patients. We establish a novel immunomodulatory role for Dkk1 in regulating tumor-induced immune suppression via targeting beta-catenin in MDSCs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available